19 results about "Cytostatic agents" patented technology

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

To provide an improved treatment strategy for multiple sclerosis (MS) patients, especially for long-term treatment. In particular, B-cell depleting MS therapies are provided without unnecessarily affecting serum levels of immunoglobulins.SOLUTION: A B-cell and / or T-cell inhibitor for use in the treatment of multiple sclerosis, wherein said treatment comprises: (a) optionally administering a B-cell and / or T-cell inhibitor other than ofatumumab; (b) monitoring serum IgG levels; (c) selecting ofatumumab as a B-cell and / or T-cell inhibitor if the serum IgG level decreases. A B-cell and / or T-cell inhibitor for use.SELECTED DRAWING: None

This invention discloses the use of tumor cell inhibitors to improve the efficiency of genetic transformation in wheat, belonging to the field of mutation or genetic engineering. The technical problem addressed by this invention is how to improve the efficiency of genetic transformation in plants. The tumor cell inhibitor disclosed in this invention is at least one of a histone modification inhibitor and a serine / threonine protein kinase inhibitor. The histone modification inhibitor is the histone deacetylase inhibitor tucidinostat, and the serine / threonine protein kinase inhibitor is Torin2. The present invention discovers that treating plant genetic transformation calli with tumor cell inhibitors promotes callus differentiation into more regenerated buds, thereby improving the efficiency of genetic transformation in plants.

The present disclosure provides methods of using combination therapies to treat cancer. These methods are based on inhibiting cyclin proteins along with proteins along the Cyclin Axis. Thus, a method of the disclosure may generally be practiced by administering to an individual having cancer a cytocidal inhibitor of cyclin, along with a therapeutic agent that targets other molecules involved in pathways that promote cyclin activity. These therapeutic agents may target biomarkers on the surface of a cancer cell and that promote cyclin activity as well as intracellular proteins involved in pathways that affect, or are affected by, cyclin activity.

The application provides a tumor cell inhibitor and a preparation method and application thereof. The preparation method of the tumor cell inhibitor comprises the following steps: dissolving an intermediate compound, 3, 4, 5-trimethoxy aniline, in 1, 4-dioxane, adding p-toluenesulfonamide to carry out a reaction, and obtaining a reaction solution; mixing the reaction solution with silica gel, spinning dry, and carrying out column chromatography purification to obtain the tumor cell inhibitor. The tumor cell inhibitor has a significant inhibitory effect on the proliferation, clone formation, migration and invasion of tumor cells, and has a good anti-tumor effect.

A product comprises: (a) a vector for specific expression of liver and / or spleen phagocytes, wherein the vector comprises a transgene operably linked to one or more expression control sequences; and (b) an immune checkpoint inhibitor or a Tr1 cell inhibitor.

Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

A novel antigen binding molecular form is provided. Comprising a non-naturally configured Fab domain, ABM conjugates comprising the ABM and a cytotoxic or cytostatic agent, pharmaceutical compositions containing the ABM and ABM conjugates, methods of using the ABM, ABM conjugates and pharmaceutical compositions for the treatment of cancer, nucleic acids encoding the ABM, and methods of using the ABM conjugates. A cell engineered to express the ABM and a method of producing the ABM.

The invention discloses a tumor cell inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The core skeleton of the tumor cell inhibitor is Ph-CH2-C (= O)-NH-Ph '-CH = N-Ph '', the preparation method comprises the two steps of preparing an intermediate A through condensation purification of a 2-aminophenylacetic acid derivative and substituted benzaldehyde and preparing a target compound through reaction purification of the intermediate A and substituted acyl chloride, the steps are simple, the conditions are mild, and the yield is high. Experiments prove that the inhibitor has a remarkable proliferation inhibition effect on tumor cells of liver cancer, lung cancer, breast cancer and the like, dose-dependent inhibition is performed on the growth of transplanted tumors in vivo, the acute toxicity is low, the toxicity to normal cells is small, and the safety is superior to that of cis-platinum. The compound disclosed by the invention can be used for preparing tumor treatment medicines, can be prepared into oral preparations and injection preparations, and has a wide clinical application prospect.

The application discloses a kind of by adjusting cannabinoid system and its downstream passage to prevent and / or treat chronic pruritus, it is related to the field of biological medicine technology.It is specifically related to at least one of CB2R agonist, microglial cell inhibitor, p-p38 inhibitor, IL-1 beta signal blocking agent in the application of preparation of the drug for preventing and / or treating chronic pruritus.The application first proves that CB2R expressed in spinal cord microglial cell plays an indispensable role in the formation and maintenance process of chronic pruritus, and by targeting CB2R expressed in spinal cord microglial cell, the function of microglial cell becomes a new treatment way of chronic pruritus.CB2R agonist, microglial cell inhibitor, p-p38 inhibitor, IL-1 beta signal blocking agent can effectively reduce spontaneous scratching times.

Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

The invention belongs to the technical field of medical instruments, and discloses a low-temperature storage device for cancer cell inhibitors, a low-temperature storage box is connected with a first spring, the first spring is connected with a supporting plate, the supporting plate is rotatably connected with a rotating cylinder, the rotating cylinder is provided with a plurality of clamping blocks, the top of each clamping block is provided with an inclined part, and the clamping blocks are connected with a fixing assembly; the low-temperature storage box is connected with a limiting cylinder, and a plurality of first clamping grooves and second clamping grooves which are alternately arranged are formed in the bottom of the limiting cylinder. A push cylinder is slidably connected into the limiting cylinder, and sawteeth matched with the inclined part of the clamping block are arranged on the edge of the bottom of the push cylinder. The top of the push cylinder is connected with a button; the top of the low-temperature storage box is provided with a concave part, the concave part is provided with an opening, and the opening is detachably connected with an end cover assembly. The technical problems that when some existing low-temperature storage devices take and place medicines, the temperature in the box is likely to rise suddenly, the set temperature can be recovered after a door is opened and closed for a long time, medicine activity decline is aggravated, and the medicines are likely to be polluted due to manual medicine taking are solved.

The invention relates to a B cell inhibitor and application thereof in preparation of drugs for treating xerophthalmia. The present invention relates to a B cell activity inhibitor selected from the group consisting of formononetin; formononin; astragaloside IV; total flavonoids of an astragalus extract; the components are astragaloside IV and formononetin; astragaloside IV and formononin; the composition is prepared from astragaloside I, astragaloside IV, formononin and formononetin. Compared with the side effect of cyclosporine in the prior art (which is within the renal toxicity of 1 / 3 of a patient who takes the medicine), the astragalus extract general flavone has the effect of inhibiting the activity of B cells so as to inhibit humoral immunity. On the basis of the research on the disease mechanism of pSS, the specific astragalus membranaceus extract general flavone which can be used as a medicine for administration and a medicine for instillation is developed.

Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

A novel antigen binding molecular form is provided. Comprising a non-naturally configured Fab domain, ABM conjugates comprising the ABM and a cytotoxic or cytostatic agent, pharmaceutical compositions containing the ABM and ABM conjugates, methods of using the ABM, ABM conjugates and pharmaceutical compositions for the treatment of cancer, nucleic acids encoding the ABM, and methods of using the ABM conjugates. A cell engineered to express the ABM and a method of producing the ABM.

Provided and exemplified herein are inhibitors of B-reg cells (regulatory B cells) for use in a combination therapy with an ICI. Useful B-reg inhibitors include antibodies that bind CD19 and CD38, for example, a bispecific antibody that binds CD19 and CD38. Such bispecific antibodies that bind CD19 and CD38 can be characterized by an antibody comprising a CD19-binding domain and a CD38-binding domain.

Provided herein are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: (I), the substituents of which are as defined herein. Also provided are conjugates of formula (XI), or a pharmaceutically acceptable salt or solvate thereof: (XI), the substituents of which are as defined herein. Also provided are pharmaceutical compositions comprising the compounds or conjugates, as well as use of the compounds or conjugates as a medicament. Also provided are compounds, conjugates or compositions for use in the treatment of cancer. Also provided is the use of the compounds, conjugates or compositions as cytostatic agents.

An organism comprising (a) a vector for phagocytic cell-specific expression of the liver and / or spleen, wherein the vector comprises a transgene operably linked to one or more expression regulatory sequences, and (b) an immune checkpoint inhibitor or a Tr1 cell inhibitor.